Fact sheet -Updated November 2015
The Priority medicines for mothers and children 2011 list was updated following the 18th Expert Committee Meeting
on Selection and Use of Medicines, the release of new treatment guidelines and feedback from partners following
the 2011 version. In alignment with the UN Global strategy f...or women’s and children’s health; and the recently
launched UN Commission on life‐saving commodities for women and children, the title of this updated list is
renamed as Priority Life‐Saving Medicines for Women and Children.
more
Lancet Respir Med 2017; 5: 291–360Vol, 5 April 2017
2nd edition. There have been many requests over the past few years for advice about what information should be included in a patient record for leprosy. The patient record should contain the essential information for the clinical management of the patients, for monitoring adherence to MDT, and for r...eporting to the national programmes and to WHO. Patient records vary between countries due to differences in health systems and are modified from time to time. The Model Patient Record is recommended as a reference and as a check list when evaluating programmes and when reviewing existing patient records.
more
2018
Vol.5 No.2:73
DOI: 10.21767/2254-9137.100092
Health Systems and Policy Research ISSN 2254-9137
WHO
Considering programmatic implications of rising levels of HIV drug resistance: finalizing the Global Action Plan
Webinars 12 13 Dec 2016
Guidelines for Therapy and Management of Acute Coronary Syndrome in Indonesia
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.